Alzinova AB interim report January – March 2021
The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the first quarter 2021.Three months, January - March 2021 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -1,463,253 SEK (-1,774,906 SEK). · Earnings per share amounted to -0.09 SEK (-0.23 SEK). · Equity ratio amounted to 93.6 % (91.8 %). Significant events during January – March 2021 · Alzinova announced that the drug substance for the vaccine ALZ-101 is manufactured and meets the requirements for the upcoming Phase 1b clinical